This article has been reviewed and updated as of April 13, 2021.
On April 13, 2021, the U.S. Food and Drug Administration (FDA) and U.S. Centers for Disease Control and Prevention (CDC) asked states to temporarily halt using the Johnson & Johnson’s COVID-19 vaccine “out of an abundance of caution” after receiving six reports of a rare and severe type of blood clot forming in individuals after receiving the vaccine. CreakyJoints is monitoring this news closely and will keep readers updated as more information is released.
Now that that the U.S. Food and Drug Administration (FDA) has issued emergency use authorization (EUA) for the Johnson & Johnson COVID-19 vaccine, people who take immunosuppressant medications, are immunocompromised, or who have autoimmune conditions have questions and concerns about what this development means for them.
Ankylosing spondylitis and heart disease: What to know medicalnewstoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalnewstoday.com Daily Mail and Mail on Sunday newspapers.
Share:
ENCINO, Calif., Dec. 16, 2020 /PRNewswire-PRWeb/ Dr. Pamela Weiss, MD, MSCE has been appointed Chair of SAA s Medical & Scientific Advisory Board (MSAB). Dr. Weiss is an attending physician in the Division of Rheumatology and a Core Faculty Member of the Center for Pediatric Clinical Effectiveness at Children s Hospital of Philadelphia (CHOP). She is also an Associate Professor of Pediatrics and Epidemiology at the Perelman School of Medicine at the University of Pennsylvania.
Dr. Weiss has a distinguished history of awards, honors, fellowships, and appointments. Her research focus is on the early diagnosis, accurate phenotyping, and targeted treatment of children with spondyloarthritis (SpA). She has over a decade of experience leading clinical research endeavors, including multicenter research and research involving international collaborations. She engaged rheumatologists from around the world to develop the Juvenile SpA Disease Activity (JSpADA) measure that reflects